Who: Eli Lilly
Based: United States
2006 Pipeline Budget: $3.47 billion (â‚¬2.37B)
2007 Pipeline News: Lilly's biggest hope right now is prasrugel, an anti-clotting drug designed to take on the blockbuster Plavix. In a recent trial prasugrel outperformed Plavix when it came to reducing the number of heart attacks and other significant events. However, prasrugel demonstrated an increased number of bleeding incidents, leading analysts to question whether the FDA will approve the drug. Other than prasrugel, analysts recently noted that there are no other potential blockbusters in Lilly's pipeline. This is extremely bad news for Lilly: A series of upcoming patent expirations could potentially trim up to 60 percent of its revenue.
Prasugrel - Acute coronary syndrome
Enzastaurin - Non-hodgkin's lymphoma
Arzoxifene - Osteoporosis & prevention of breast cancer
Company Pipeline Site: Link